IP Library › Granted Patent US 8,512,715
Granted Patent B2
US 8,512,715 · App. 12/541,221 · Granted Aug 20, 2013

Apparatus and method for treating a neuromuscular defect

Inventor: Francis A. Papay (Westlake, OH)
Assignee: The Cleveland Clinic Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,512,715
App. No.
12/541,221
Granted
Aug 20, 2013
Kind
B2
Abstract

A method is provided for treating a neuromuscular defect in a subject. One step of the method includes locating a target nerve. After locating the target nerve, a treatment probe is provided. The treatment probe includes an elongated body member having a proximal end portion and a distal end portion. The distal end portion includes an energy delivery mechanism for stimulating or ablating the target nerve, a monitoring mechanism, and a fluid aspiration/delivery mechanism. Next, the target nerve is verified as an appropriate target for ablation by stimulating and then monitoring the target nerve via the energy delivery mechanism and the monitoring mechanism, respectively. After verifying the target nerve, a tumescent fluid is injected into the tissue surrounding the target nerve. An electric current is then delivered to the energy delivery mechanism to substantially ablate the target nerve.

Claims (19)

1. A method for treating a neuromuscular defect in a subject, said method comprising the steps of:

locating a target nerve;

providing a treatment probe, the treatment probe comprising an elongated body member having a proximal end portion and a distal end portion, the distal end portion including an energy delivery mechanism for stimulating or ablating the target nerve, a monitoring mechanism, and a fluid aspiration and delivery mechanism;

verifying that the target nerve is an appropriate target for ablation by stimulating and then monitoring the target nerve via the energy delivery mechanism and the monitoring mechanism, respectively;

injecting a tumescent fluid into the tissue surrounding the target nerve; and

delivering an electric current to the energy delivery mechanism to substantially ablate the target nerve;

wherein said step of injecting a tumescent fluid into the tissue surrounding the target nerve protects superficial tissue planes from inadvertent heat damage and enhances electro-mechanical conduction during delivery of electric current to the target nerve;

wherein said injecting step and said delivering step are performed using the same treatment probe;

wherein delivery of the electric current temporarily or permanently inhibits muscle contraction;

wherein the neurological movement disorder is selected from the group consisting of torticollis, blepharospasm, and uncontrolled grimacing.

2. The method of claim 1 , wherein said step of locating a target nerve includes monitoring electrical activity of the target nerve via the monitoring mechanism.

3. The method of claim 2 , wherein electromyographic monitoring is used to monitor the electrical activity of the target nerve.

4. The method of claim 1 , wherein said step verifying that the target nerve is an appropriate target for ablation further comprises the steps of:

applying a stimulation current to the target nerve via the energy delivery mechanism; and

monitoring the subject for measurable result indicative of the appropriate target nerve.

5. The method of claim 4 , wherein the measurable result indicative of the appropriate target nerve is at least one of an observable clinical result, an electromyographic signal or pattern, and a change in pain perception.

6. The method of claim 1 , wherein said step of injecting a tumescent fluid into the tissue surrounding the target nerve further includes injecting a pharmacological agent into the tissue surrounding the target nerve.

7. The method of claim 6 , wherein the pharmacological agent is selected from the group consisting of an anesthetic agent, an anti-inflammatory agent, an electrolyte solution, and a neurotoxic agent.

8. The method of claim 7 , wherein the neurotoxic agent comprises Botulinum toxin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2010
From: PAPAY, FRANCIS A.
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 023949/0181 →
Continuity (2)
Provisional Application 61089015 · Aug 14, 2008
Related Publication 20100143413A1 · Jun 10, 2010